KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment

Fluoropyrimidine-based chemotherapy plus antibody therapy is currently the standard first-line treatment for metastatic colorectal cancer (mCRC). In this study, we investigated the hypothesis that mutations in several of the targeted oncogenes are correlated with treatment outcomes in mCRC patients...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: SOEDA, HIROSHI, SHIMODAIRA, HIDEKI, WATANABE, MIKA, SUZUKI, TAKAO, GAMO, MAKIO, TAKAHASHI, MASANOBU, KOMINE, KEIGO, KATO, SHUNSUKE, ISHIOKA, CHIKASHI
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: D.A. Spandidos 2014
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3999142/
https://ncbi.nlm.nih.gov/pubmed/24772300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.254
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg